Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AR-17043 Ophthalmic Solution
AR-17043 · 1 trial · 2 indications
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the four measurements.
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the three measurements.
| Arm | Type | Description |
|---|---|---|
| AR-17043 low concentration (Stage 1) | EXPERIMENTAL | AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| AR-17043 medium concentration (Stage 1) | EXPERIMENTAL | AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| AR-17043 high concentration (Stage 1) | EXPERIMENTAL | AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| AR-17043 vehicle (Stage 1) | PLACEBO_COMPARATOR | AR-17043 Vehicle, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| Rhopressa (Stage 1) | ACTIVE_COMPARATOR | Netarsudil 0.02% Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| PG043 low concentration (Stage 2) | EXPERIMENTAL | PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| PG043 high concentration (Stage 2) | EXPERIMENTAL | PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| AR-17043 high concentration (Stage 2) | ACTIVE_COMPARATOR | AR-17043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| Latanoprost (Stage 2) | ACTIVE_COMPARATOR | Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| Rocklatan (Stage 2) | ACTIVE_COMPARATOR | Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| Name | Type | Description |
|---|---|---|
| AR-17043 Ophthalmic Solution | DRUG | Investigational monotherapy supplied in three concentration levels: low, medium, high |
| PG043 Ophthalmic Solution | DRUG | Investigational fixed dose combination supplied in two concentration levels: low and high |
| Latanoprost 0.005% Ophthalmic Solution | DRUG | Marketed monotherapy |
| Netarsudil 0.02% Ophthalmic Solution | DRUG | Marketed monotherapy |
| Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution | DRUG | Marketed fixed dose combination |
| AR-17043 Vehicle | DRUG | Placebo comparator |
Stage 1 Key Inclusion Criteria; * Diagnosis of OAG or OHT in both eyes. * High unmedicated IOP measurements in the study eye as specified in the protocol. * Corrected visual acuity equal to or better than +1.0 logMAR (Snellen equivalent equal to or better than 20/200) in the study eye. * Other prot...
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
AR-17043 is an investigational ophthalmic solution being developed for open angle glaucoma and ocular hypertension. It is a small molecule eye drop studied in a Phase 2 clinical trial. It is not yet approved for commercial use.
AR-17043 is being developed by Alcon Inc., which trades on the New York Stock Exchange under the ticker ALC. Alcon is an eye care company focused on surgical and vision care products.
AR-17043 is in Phase 2 clinical development. One Phase 2 trial has been completed, and no active trials are currently listed. It remains an investigational therapy and has not been approved by the FDA.
AR-17043 has been studied in a single Phase 2 trial, NCT06441643, titled Next Generation Rocklatan. The trial enrolled 426 participants with open angle glaucoma or ocular hypertension in the United States and has been completed.
Yes, AR-17043 Ophthalmic Solution is another name for AR-17043. Both refer to the same investigational eye drop developed by Alcon for open angle glaucoma and ocular hypertension.